Transforming Oncology through Real-World Data

Harnessing real-world evidence to drive innovation in cancer research and care

Real-world data plays a crucial role in oncology research and drug development by providing a more comprehensive, real-world perspective on how treatments work, their effectiveness in diverse patient populations, and their long-term safety and cost-effectiveness. This data is increasingly recognized as a valuable resource in the oncology field, enabling more informed decision-making for clinicians, researchers, regulators, and patients.

Unlocking Cancer's Secrets: How Real-World Data is Revolutionizing Oncology

Real-world data from electronic health records, cancer registries, and claims databases are providing invaluable insights into non-small cell lung cancer, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and other hematologic malignancies.

Analyzing real-world data is enabling researchers to better understand prognosis, treatment responses, side effects, and outcomes in diverse patient populations.

For lung cancer, real-world data analysis is being used to study immune checkpoint inhibitor effectiveness, identify predictive biomarkers, and assess quality of life.
For follicular and marginal zone lymphomas, real-world data helps elucidate prognosis, inform treatment sequencing, and characterize rare transformations.
For chronic lymphocytic leukemia, real-world data sheds light on outcomes with novel targeted therapies.

By harnessing real-world evidence, researchers can complement clinical trials and drive advances in oncology care. BC Platforms, through globally sourced and analysis-ready oncology data, support your research to achieve these important goals.

BC Platforms representative experience in Oncology

The future of cancer care lies in our ability to translate real-world insights into improved treatments and outcomes. As real-world data in oncology continues to grow in scope and scale, its potential to drive advances across the cancer care continuum will be profound. By harnessing real-world data, we can usher in an era of data-driven, personalized medicine that transforms how cancer is prevented, detected, treated, and monitored. The promise of real-world data in oncology is clear - together, let's realize it for the benefit of patients worldwide. Our comprehensive real-world data solutions are ready to empower your organization's efforts and accelerate progress against cancer. From Data to Health.

NON-SMALL CELL LUNG CANCER

Obtaining NSCLC patient data and samples to perform assay validation.

FOLLICULAR LYMPHOMA
MARGINAL ZONE LYMPHOMA

Retrospective, multicenter, non-interventional study to generate a Real-world comparator cohort In adult patients with relapsed or Refractory Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).

CHRONIC LYMPHOCYTIC LEUKEMIA

SMALL LYMPHOCYTIC LYMPHOMA

Retrospective, multicenter, non-interventional study to generate real-world evidence for subjects with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with prior exposure to a Bruton’s tyrosine kinase inhibitor.

MULTIPLE MYELOMA

Bridging the gaps between real-world data and clinical trial data. Validating data and trial methodology. Identify indications where a drug may provide meaningful benefit for patients.

Current Cancer Research Initiatives BC Platforms is contributing to

iDx LUNG

Improving detection of lung cancer

Recognizing the urgent need for improved detection and treatment of lung cancer, BC Platforms has also delivered a state-of-the-art data platform for a UK research consortium project termed iDx-LUNG. The consortium is led by the Universities of Southampton and Leeds, together with healthcare, diagnostics and informatics companies, to test the best way of detecting cancers at a stage when they can still be cured, linking to the NHS England Lung Health Checks programme. In addition to BC Platforms, the research collaborators include Johnson & Johnson, Roche, Oncimmune, Inivata and others.

ONCOVALUE

Value-based oncology care

BC Platforms has partnered with an EU-funded, AI-driven cancer data initiative ONCOVALUE. This collaborative effort aims to develop novel AI-based tools to automate the collection and analytics of clinical data, assessing in real-time, real-life effectiveness of novel cancer therapies. This will support the development of effective medicines, reduce spending on drugs that yield little benefit and enable oncologists to promote value-based cancer care.

Oncology Real-World Data Availability Snapshot

To learn more about BC Platforms' representative experience in Oncology, download our RWD Availability Snapshot by filling out the form.